Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Income from Continuing Operations: 2023-2025

Historic Income from Continuing Operations for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.0 million.

  • Mereo BioPharma Group's Income from Continuing Operations rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Income from Continuing Operations stood at -$7.0 million for Q3 2025, which was up 51.94% from -$14.6 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Income from Continuing Operations high stood at -$1.8 million for Q2 2023, and its period low was -$15.0 million during Q3 2024.
  • Over the past 3 years, Mereo BioPharma Group's median Income from Continuing Operations value was -$9.1 million (recorded in 2023), while the average stood at -$9.7 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 599.89% in 2024, then spiked by 53.18% in 2025.
  • Mereo BioPharma Group's Income from Continuing Operations (Quarterly) stood at -$9.1 million in 2023, then climbed by 22.65% to -$7.0 million in 2024, then soared by 53.18% to -$7.0 million in 2025.
  • Its Income from Continuing Operations stands at -$7.0 million for Q3 2025, versus -$14.6 million for Q2 2025 and -$12.9 million for Q1 2025.